Last updated on January 2020

A Single Ascending Dose Study to Investigate the Safety Tolerability Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants

Brief description of study

Study BP41192 is a randomized, adaptive, placebo-controlled parallel group study to investigate the safety, tolerability, immunogenicity and pharmacokinetics of single-ascending intravenous doses of RO7126209 in healthy participants. RO7126209 is being developed for the treatment of Alzheimer's Disease.

Detailed Study Description

This study uses a parallel group design, with participants recruited in 5 planned sequential cohorts. Participants will receive a single IV dose of either RO7126209 or placebo. RO7126209 doses will be administered in ascending order. After the starting dose, subsequent doses will be selected in an adaptive manner during study conduct based on emerging safety, tolerability and PK data.

Clinical Study Identifier: NCT04023994

Find a site near you

Start Over

PRA Health Sciences

Raleigh, NC United States
  Connect »